In April this year, the European Parliament voted for a new law to make results from clinical trials more easily available, a move that was welcomed by many as a step in the right direction. However, a further draft of the policy has introduced barriers to access to clinical trial data that, AllTrials claims, ‘would make the job of researchers who want to scrutinise it almost impossible’.
This response has proven unsatisfactory to AllTrials, who, along with Glenis Willmott MEP, are calling for Professor Rasi to delay finalising the policy. ‘If the EMA allows its new policy to be based on out of date attitudes it risks losing the trust of patients, policy makers and healthcare professionals,’ AllTrials says. ‘We urge you to revise your policy to reflect your earlier support for the public interest in better medicine.’